CLIN CHEM LAB MED:对硫酸吲哚酚试剂盒NIPRO的性能评价

2019-11-03 MedSci MedSci原创

目前,肾脏疾病与心血管疾病(CVD)之间的关系被称为心肾综合征。硫酸吲哚氧基是加速心肾综合征进展的尿毒症毒素之一。本报告提出了一种更简便的测量方法。

目前,肾脏疾病与心血管疾病(CVD)之间的关系被称为心肾综合征。硫酸吲哚氧基是加速心肾综合征进展的尿毒症毒素之一。本报告提出了一种更简便的测量方法。

我们评估了载于LABOSPECT 008上的IS检测试剂盒“NIPRO”的分析性能。评价分析性能包括准确度、精密度、稀释线性度、检出限(LOD)、定量限(LOQ)、回收率试验、干扰试验以及与高效液相色谱法(HPLC)测定结果的比较。

研究显示,总精度显示<变异系数在5.3%浓度的3.57 -277.73μmol / L,稀释线性和满意的结果观察,LOD,定量限,复苏和干扰测试。IS检测试剂盒“NIPRO”HPLC常规方法相关性高(r = 0.993)

研究表明,IS检测试剂盒“NIPRO”显示了令人满意的分析性能,这表明它可能很快成为另一种测量循环IS的常用方法。

原始出处:

Yuki FushimiJunko TatebePerformance evaluation of an Indoxyl Sulfate Assay Kit NIPRO

本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1991082, encodeId=d8db199108283, content=<a href='/topic/show?id=69bd91e371a' target=_blank style='color:#2F92EE;'>#试剂盒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91737, encryptionId=69bd91e371a, topicName=试剂盒)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Wed Feb 12 21:28:00 CST 2020, time=2020-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444592, encodeId=49e3144459276, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Tue Nov 05 13:28:00 CST 2019, time=2019-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602207, encodeId=fe0e160220e1a, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Tue Nov 05 13:28:00 CST 2019, time=2019-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610096, encodeId=7e2c1610096bb, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Nov 05 13:28:00 CST 2019, time=2019-11-05, status=1, ipAttribution=)]
    2020-02-12 tastas
  2. [GetPortalCommentsPageByObjectIdResponse(id=1991082, encodeId=d8db199108283, content=<a href='/topic/show?id=69bd91e371a' target=_blank style='color:#2F92EE;'>#试剂盒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91737, encryptionId=69bd91e371a, topicName=试剂盒)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Wed Feb 12 21:28:00 CST 2020, time=2020-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444592, encodeId=49e3144459276, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Tue Nov 05 13:28:00 CST 2019, time=2019-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602207, encodeId=fe0e160220e1a, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Tue Nov 05 13:28:00 CST 2019, time=2019-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610096, encodeId=7e2c1610096bb, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Nov 05 13:28:00 CST 2019, time=2019-11-05, status=1, ipAttribution=)]
    2019-11-05 huagfeg
  3. [GetPortalCommentsPageByObjectIdResponse(id=1991082, encodeId=d8db199108283, content=<a href='/topic/show?id=69bd91e371a' target=_blank style='color:#2F92EE;'>#试剂盒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91737, encryptionId=69bd91e371a, topicName=试剂盒)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Wed Feb 12 21:28:00 CST 2020, time=2020-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444592, encodeId=49e3144459276, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Tue Nov 05 13:28:00 CST 2019, time=2019-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602207, encodeId=fe0e160220e1a, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Tue Nov 05 13:28:00 CST 2019, time=2019-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610096, encodeId=7e2c1610096bb, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Nov 05 13:28:00 CST 2019, time=2019-11-05, status=1, ipAttribution=)]
    2019-11-05 sunylz
  4. [GetPortalCommentsPageByObjectIdResponse(id=1991082, encodeId=d8db199108283, content=<a href='/topic/show?id=69bd91e371a' target=_blank style='color:#2F92EE;'>#试剂盒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91737, encryptionId=69bd91e371a, topicName=试剂盒)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Wed Feb 12 21:28:00 CST 2020, time=2020-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444592, encodeId=49e3144459276, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Tue Nov 05 13:28:00 CST 2019, time=2019-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602207, encodeId=fe0e160220e1a, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Tue Nov 05 13:28:00 CST 2019, time=2019-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610096, encodeId=7e2c1610096bb, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Nov 05 13:28:00 CST 2019, time=2019-11-05, status=1, ipAttribution=)]

相关资讯

Eur Heart J:非布索坦预防脑、心血管或肾脏疾病疗效

由此可见,非布索坦可降低尿酸并延缓肾功能障碍的进展。

肾内科常见尿液检查的临床意义,你知道多少?

肾脏内科常用的尿液检查主要包括尿常规+沉渣镜检、尿红细胞相位、肾脏早期损伤指标(白蛋白/肌酐比值、NAG酶、α1微球)、尿培养、24小时尿液检查(尿蛋白定量、尿离子定量、尿酸定量、尿轻链定量、肌酐清除率)、尿渗透压、尿蛋白电泳、尿免疫固定电泳。尽量清晨空腹留取尿标本,并避开月经期,也就是说要在月经结束3天以后,避免污染标本,导致检查结果不准确或假阳性。

JACC:慢性肾脏疾病患者的心衰住院风险研究

目前,对于慢性肾脏疾病(CKD)相关的心衰住院率、重复住院率和心衰住院预后尚不清楚。本研究纳入分析了CRIC临床试验中的3791名CKD患者,心衰的住院率是5.8/100人年,与心衰伴射血分数降低患者相比,心衰伴保留型射血分数的患者住院率更高。调整后的心衰发生率在eGFR更低的患者的中更高。相似的,心衰的住院风险在尿白蛋白与肌酐比值更高的患者中更高。总体来看,有20.6%的患者在30天内右心衰的再

JACC:慢性肾脏疾病可增加主动脉狭窄风险!

慢性肾脏疾病(CKD)和主动脉狭窄(AS)有许多共同的危险因素。本研究的目的旨在评估肾功能不全是否与AS的发展相关。本研究纳入了SCREAM 研究中的1121875名无AS诊断的城市居民,平均年龄为50岁(IQR:36-64岁),女性占54%,平均估计肾小球滤过率(eGFR)为96 ml/min/1.73 m2 (IQR:82 - 109 ml/min/1.73 m2),有66949名(6%)对象

盘点:肾脏相关疾病研究进展

【1】Brit J Cancer:类血管生成素蛋白3能够阻断FAK的细胞核输入并有助于索拉非尼响应  索拉非尼不良的药物反应是一个重要的挑战。不良药物反应减少了肾细胞癌(RCC)患者的临床益处。因此,阐释恢复索拉非尼治疗响应的潜在机制具有中重要的意义。最近,有研究人员利用蛋白免疫印迹和免疫组化技术在2个RCC患者群体中测量了类血管生成素蛋白3(ANGPTL3)含量水平。在R

PNAS:基因编辑在肾脏疾病中的应用

科学家首次确定了如何阻止先天性肾脏疾病,这可能为今后的个性化治疗铺平道路。 英国纽卡斯尔大学的研究人员在细胞和小鼠模型中表明,基因编辑可用于Joubert综合征,以阻止携带CEP290缺陷基因对患者肾脏造成损害。Joubert综合征是一种脑部疾病,引起不同程度的身体、精神和视觉障碍。大约80000个新生儿中有一个会得这种病,其中的三分之一患者会导致肾衰竭。